同源和异源疫苗应用于SARS-CoV-2组粒变异的疗效:马尼萨Celal Bayar大学医护人员队列研究

IF 1.1 4区 医学 Q4 MICROBIOLOGY
Kübra Çiçek, Yunus Özkaya, Erhan Eser, Zeynep Ceyda Buran, Zeynep Öykü Öztürk Arıkan, Sinem Akçalı, Pınar Erbay Dündar, Beyhan Cengiz Özyurt, Şebnem Şenol Akar, Deniz Özer, Ferya Karadağ Yalçın
{"title":"同源和异源疫苗应用于SARS-CoV-2组粒变异的疗效:马尼萨Celal Bayar大学医护人员队列研究","authors":"Kübra Çiçek,&nbsp;Yunus Özkaya,&nbsp;Erhan Eser,&nbsp;Zeynep Ceyda Buran,&nbsp;Zeynep Öykü Öztürk Arıkan,&nbsp;Sinem Akçalı,&nbsp;Pınar Erbay Dündar,&nbsp;Beyhan Cengiz Özyurt,&nbsp;Şebnem Şenol Akar,&nbsp;Deniz Özer,&nbsp;Ferya Karadağ Yalçın","doi":"10.5578/mb.20239918","DOIUrl":null,"url":null,"abstract":"<p><p>This study was aimed to determine the efficacy of homologous (only CoronaVac or only Pfizer-BioNTech) and heterologous (CoronaVac and Pfizer-BioNTech) vaccines during the period when the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron variant was dominant in Türkiye. Coronavirus disease-2019 (COVID-2019) infection was confirmed by reverse transcriptase polymerase chain reaction and data on vaccination status against COVID-19 were evaluated during the period of 15 January 2022-1 May 2022 when the SARS-CoV-2 Omicron variant was dominant among 1854 employees followed in the SARS-CoV-2 Vaccine Cohort of Manisa Celal Bayar University (MCBU) Hospital Health Workers. Two separate reference groups were used in the evaluation of vaccine efficacy: those who were never vaccinated and those who received only two doses of CoronaVac. The efficacy of homologous and heterologous vaccine models was evaluated with relative risks and attributable risk percentages. MS Excel, SPSS 23.0 and STATA 14.1 package programs were used for statistical analysis. The mean age of the participants was 36.6 ± 10.0. During the period from January 15th to May 1st 2022, 372 hospital workers were infected with COVID-19. Taking the never vaccinated as the reference group, the most effective model was found to be only the three or more doses of the Pfizer-BioNTech primary vaccination model (85.8%, 95% CI= 40.7-96.6). Models consisting of a single dose of CoronaVac (6.5%, 95% CI= -56.3-44.2) or a single dose of Pfizer-BioNTech (17.7%, 95% CI= -30.2-48.0) booster dose administered after two doses of primary CoronaVac vaccination was not found to be effective against the SARS-CoV-2 Omicron variant. When only two doses of primary CoronaVac vaccination model was taken as the reference group, the model consisting of two doses CoronaVac followed by two Pfizer-BioNTech booster doses was effective as 38.4% (95% CI= 15.4-55.3), whereas three doses of Pfizer-BioNTech booster model was effective as 56.4% (95% CI= 33.9-71.3). To conclude, none of the models other than the homologous or heterologous vaccine models containing at least three doses of Pfizer-BioNTech vaccine were effective compared to those unvaccinated. Compared with those who received only two doses of primary Coronavac, models with at least three doses of Pfizer-BioNTech reminder doses were more effective against the Omicron variant than other models.</p>","PeriodicalId":18509,"journal":{"name":"Mikrobiyoloji bulteni","volume":"57 2","pages":"238-251"},"PeriodicalIF":1.1000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Efficacy of Homologous and Heterologous Vaccine Applications on SARS-CoV-2 Omicron Variant: Cohort of Manisa Celal Bayar University Healthcare Workers].\",\"authors\":\"Kübra Çiçek,&nbsp;Yunus Özkaya,&nbsp;Erhan Eser,&nbsp;Zeynep Ceyda Buran,&nbsp;Zeynep Öykü Öztürk Arıkan,&nbsp;Sinem Akçalı,&nbsp;Pınar Erbay Dündar,&nbsp;Beyhan Cengiz Özyurt,&nbsp;Şebnem Şenol Akar,&nbsp;Deniz Özer,&nbsp;Ferya Karadağ Yalçın\",\"doi\":\"10.5578/mb.20239918\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This study was aimed to determine the efficacy of homologous (only CoronaVac or only Pfizer-BioNTech) and heterologous (CoronaVac and Pfizer-BioNTech) vaccines during the period when the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron variant was dominant in Türkiye. Coronavirus disease-2019 (COVID-2019) infection was confirmed by reverse transcriptase polymerase chain reaction and data on vaccination status against COVID-19 were evaluated during the period of 15 January 2022-1 May 2022 when the SARS-CoV-2 Omicron variant was dominant among 1854 employees followed in the SARS-CoV-2 Vaccine Cohort of Manisa Celal Bayar University (MCBU) Hospital Health Workers. Two separate reference groups were used in the evaluation of vaccine efficacy: those who were never vaccinated and those who received only two doses of CoronaVac. The efficacy of homologous and heterologous vaccine models was evaluated with relative risks and attributable risk percentages. MS Excel, SPSS 23.0 and STATA 14.1 package programs were used for statistical analysis. The mean age of the participants was 36.6 ± 10.0. During the period from January 15th to May 1st 2022, 372 hospital workers were infected with COVID-19. Taking the never vaccinated as the reference group, the most effective model was found to be only the three or more doses of the Pfizer-BioNTech primary vaccination model (85.8%, 95% CI= 40.7-96.6). Models consisting of a single dose of CoronaVac (6.5%, 95% CI= -56.3-44.2) or a single dose of Pfizer-BioNTech (17.7%, 95% CI= -30.2-48.0) booster dose administered after two doses of primary CoronaVac vaccination was not found to be effective against the SARS-CoV-2 Omicron variant. When only two doses of primary CoronaVac vaccination model was taken as the reference group, the model consisting of two doses CoronaVac followed by two Pfizer-BioNTech booster doses was effective as 38.4% (95% CI= 15.4-55.3), whereas three doses of Pfizer-BioNTech booster model was effective as 56.4% (95% CI= 33.9-71.3). To conclude, none of the models other than the homologous or heterologous vaccine models containing at least three doses of Pfizer-BioNTech vaccine were effective compared to those unvaccinated. Compared with those who received only two doses of primary Coronavac, models with at least three doses of Pfizer-BioNTech reminder doses were more effective against the Omicron variant than other models.</p>\",\"PeriodicalId\":18509,\"journal\":{\"name\":\"Mikrobiyoloji bulteni\",\"volume\":\"57 2\",\"pages\":\"238-251\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Mikrobiyoloji bulteni\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5578/mb.20239918\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mikrobiyoloji bulteni","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5578/mb.20239918","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

本研究旨在确定同源(仅CoronaVac或仅辉瑞- biontech)和异源(CoronaVac和辉瑞- biontech)疫苗在严重急性呼吸综合征冠状病毒-2 (SARS-CoV-2) Omicron变体在 rkiye中占主导地位期间的疗效。通过逆转录酶聚合酶链反应确认2019冠状病毒病(COVID-2019)感染,并评估2022年1月15日至2022年5月期间的COVID-19疫苗接种状况数据,当时在马尼萨Celal Bayar大学(MCBU)医院卫生工作者随访的1854名员工中,SARS-CoV-2 Omicron变体占主导地位。在评估疫苗效力时,使用了两个独立的参照组:从未接种疫苗的组和仅接种两剂冠状病毒疫苗的组。用相对危险度和归因危险度百分比评价同源和异源疫苗模型的疗效。采用MS Excel、SPSS 23.0、STATA 14.1软件包进行统计分析。参与者平均年龄为36.6±10.0岁。在2022年1月15日至5月1日期间,372名医院工作人员感染了COVID-19。以未接种疫苗为参照组,发现最有效的模型只有三剂及以上的辉瑞- biontech一次疫苗模型(85.8%,95% CI= 40.7-96.6)。在两剂CoronaVac初级疫苗接种后,由单剂CoronaVac (6.5%, 95% CI= -56.3-44.2)或单剂Pfizer-BioNTech (17.7%, 95% CI= -30.2-48.0)加强剂组成的模型未发现对SARS-CoV-2 Omicron变体有效。当仅以两剂CoronaVac初级疫苗接种模型为参照组时,两剂CoronaVac加两剂辉瑞- biontech加强疫苗接种模型的有效率为38.4% (95% CI= 15.4-55.3),而三剂辉瑞- biontech加强疫苗接种模型的有效率为56.4% (95% CI= 33.9-71.3)。综上所述,与未接种的模型相比,除了同源或异源疫苗模型外,含有至少三剂辉瑞- biontech疫苗的模型均无效。与只接受两剂初级Coronavac的模型相比,至少接受三剂辉瑞- biontech提醒剂量的模型比其他模型更有效地对抗Omicron变体。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Efficacy of Homologous and Heterologous Vaccine Applications on SARS-CoV-2 Omicron Variant: Cohort of Manisa Celal Bayar University Healthcare Workers].

This study was aimed to determine the efficacy of homologous (only CoronaVac or only Pfizer-BioNTech) and heterologous (CoronaVac and Pfizer-BioNTech) vaccines during the period when the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron variant was dominant in Türkiye. Coronavirus disease-2019 (COVID-2019) infection was confirmed by reverse transcriptase polymerase chain reaction and data on vaccination status against COVID-19 were evaluated during the period of 15 January 2022-1 May 2022 when the SARS-CoV-2 Omicron variant was dominant among 1854 employees followed in the SARS-CoV-2 Vaccine Cohort of Manisa Celal Bayar University (MCBU) Hospital Health Workers. Two separate reference groups were used in the evaluation of vaccine efficacy: those who were never vaccinated and those who received only two doses of CoronaVac. The efficacy of homologous and heterologous vaccine models was evaluated with relative risks and attributable risk percentages. MS Excel, SPSS 23.0 and STATA 14.1 package programs were used for statistical analysis. The mean age of the participants was 36.6 ± 10.0. During the period from January 15th to May 1st 2022, 372 hospital workers were infected with COVID-19. Taking the never vaccinated as the reference group, the most effective model was found to be only the three or more doses of the Pfizer-BioNTech primary vaccination model (85.8%, 95% CI= 40.7-96.6). Models consisting of a single dose of CoronaVac (6.5%, 95% CI= -56.3-44.2) or a single dose of Pfizer-BioNTech (17.7%, 95% CI= -30.2-48.0) booster dose administered after two doses of primary CoronaVac vaccination was not found to be effective against the SARS-CoV-2 Omicron variant. When only two doses of primary CoronaVac vaccination model was taken as the reference group, the model consisting of two doses CoronaVac followed by two Pfizer-BioNTech booster doses was effective as 38.4% (95% CI= 15.4-55.3), whereas three doses of Pfizer-BioNTech booster model was effective as 56.4% (95% CI= 33.9-71.3). To conclude, none of the models other than the homologous or heterologous vaccine models containing at least three doses of Pfizer-BioNTech vaccine were effective compared to those unvaccinated. Compared with those who received only two doses of primary Coronavac, models with at least three doses of Pfizer-BioNTech reminder doses were more effective against the Omicron variant than other models.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Mikrobiyoloji bulteni
Mikrobiyoloji bulteni 生物-微生物学
CiteScore
1.60
自引率
20.00%
发文量
50
审稿时长
6-12 weeks
期刊介绍: Bulletin of Microbiology is the scientific official publication of Ankara Microbiology Society. It is published quarterly in January, April, July and October. The aim of Bulletin of Microbiology is to publish high quality scientific research articles on the subjects of medical and clinical microbiology. In addition, review articles, short communications and reports, case reports, editorials, letters to editor and other training-oriented scientific materials are also accepted. Publishing language is Turkish with a comprehensive English abstract. The editorial policy of the journal is based on independent, unbiased, and double-blinded peer-review. Specialists of medical and/or clinical microbiology, infectious disease and public health, and clinicians and researchers who are training and interesting with those subjects, are the target groups of Bulletin of Microbiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信